Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Pablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, Michael Arad, Cristina Basso, Antonio Brucato, Ivana Burazor, Alida L.P. Caforio, Thibaud Damy, Urs Eriksson, Marianna Fontana, Julian D. Gillmore, Esther Gonzalez-Lopez, Martha Grogan, Stephane Heymans, Massimo Imazio, Ingrid Kindermann, Arnt V. Kristen, Mathew S. Maurer, Giampaolo MerliniAntonis Pantazis, Sabine Pankuweit, Angelos G. Rigopoulos, Ales Linhart

Research output: Contribution to journalArticlepeer-review

Abstract

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

Original languageEnglish (US)
JournalEuropean Journal of Heart Failure
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases'. Together they form a unique fingerprint.

Cite this